Literature DB >> 23178754

MLL-AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny.

S J Horton1, J Jaques, C Woolthuis, J van Dijk, M Mesuraca, G Huls, G Morrone, E Vellenga, J J Schuringa.   

Abstract

The MLL-AF9 fusion gene is associated with aggressive leukemias of both the myeloid and lymphoid lineage in infants, whereas in adults, this translocation is mainly associated with acute myeloid leukemia. These observations suggest that differences exist between fetal and adult tissues in terms of the 'cell of origin' from which the leukemia develops. Here we show that depending on extrinsic cues, human neonatal CD34(+) cells are readily immortalized along either the myeloid or lymphoid lineage upon MLL-AF9 expression and give rise to mainly lymphoid leukemia in immunocompromised mice. In contrast, immortalization of adult bone marrow CD34(+) cells is more difficult to achieve and is myeloid-biased, even when MLL-AF9 is expressed in purified hematopoietic stem cells (HSCs). Transcriptome analysis identified enrichment of HSC but not progenitor gene signatures in MLL-AF9-expressing cells. Although not observed in adult cells, neonatal cells expressing MLL-AF9 were enriched for gene signatures associated with poor prognosis, resistance to chemotherapeutic agents and MYC signaling. These results indicate that neonatal cells are inherently more prone to MLL-AF9-mediated immortalization than adult cells and suggest that intrinsic properties of the cell of origin, in addition to extrinsic cues, dictate lineage of the immortalized cell.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23178754     DOI: 10.1038/leu.2012.343

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  38 in total

1.  Chemopreventive Effects of Dietary Eicosapentaenoic Acid Supplementation in Experimental Myeloid Leukemia.

Authors:  Emily R Finch; Avinash K Kudva; Michael D Quickel; Laura L Goodfield; Mary J Kennett; Jay Whelan; Robert F Paulson; K Sandeep Prabhu
Journal:  Cancer Prev Res (Phila)       Date:  2015-08-19

2.  CDKI-73: an orally bioavailable and highly efficacious CDK9 inhibitor against acute myeloid leukemia.

Authors:  Muhammed H Rahaman; Yingyi Yu; Longjin Zhong; Julian Adams; Frankie Lam; Peng Li; Ben Noll; Robert Milne; Jun Peng; Shudong Wang
Journal:  Invest New Drugs       Date:  2018-09-08       Impact factor: 3.850

3.  Context matters in MLL-AF9-driven leukemias.

Authors:  Christopher Y Park
Journal:  Blood       Date:  2016-05-12       Impact factor: 22.113

4.  Transcription factor 4 (TCF4) expression predicts clinical outcome in RUNX1 mutated and translocated acute myeloid leukemia.

Authors:  Florentien E M In 't Hout; Mylène Gerritsen; Lars Bullinger; Bert A van der Reijden; Gerwin Huls; Edo Vellenga; Joop H Jansen
Journal:  Haematologica       Date:  2019-12-19       Impact factor: 9.941

5.  The efficiency of murine MLL-ENL-driven leukemia initiation changes with age and peaks during neonatal development.

Authors:  Theresa Okeyo-Owuor; Yanan Li; Riddhi M Patel; Wei Yang; Emily B Casey; Andrew S Cluster; Shaina N Porter; David Bryder; Jeffrey A Magee
Journal:  Blood Adv       Date:  2019-08-13

6.  Reconstruction of Human AML Using Functionally and Immunophenotypically Defined Human Haematopoietic Stem and Progenitor Cells as Targeted Populations.

Authors:  Bernd B Zeisig; Tsz Kan Fung; Estelle Troadec; Chi Wai Eric So
Journal:  Bio Protoc       Date:  2021-12-20

7.  Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.

Authors:  P Sontakke; M Carretta; J Jaques; A Z Brouwers-Vos; L Lubbers-Aalders; H Yuan; J D de Bruijn; A C M Martens; E Vellenga; R W J Groen; J J Schuringa
Journal:  Leukemia       Date:  2016-04-29       Impact factor: 11.528

Review 8.  MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies.

Authors:  Seyed Esmaeil Ahmadi; Samira Rahimi; Bahman Zarandi; Rouzbeh Chegeni; Majid Safa
Journal:  J Hematol Oncol       Date:  2021-08-09       Impact factor: 17.388

9.  11q23 abnormalities in adult Chinese patients with hematological malignancies.

Authors:  Xiaoli Zhao; Shuang Li; Nianyi Li; Rong Fan; Guowei Lin; Xiaoqin Wang
Journal:  Med Oncol       Date:  2014-07-10       Impact factor: 3.064

10.  Aberrant GSK3β nuclear localization promotes AML growth and drug resistance.

Authors:  James J Ignatz-Hoover; Victoria Wang; Nathan M Mackowski; Anne J Roe; Isaac K Ghansah; Masumi Ueda; Hillard M Lazarus; Marcos de Lima; Elisabeth Paietta; Hugo Fernandez; Larry Cripe; Martin Tallman; David N Wald
Journal:  Blood Adv       Date:  2018-11-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.